- We are committed to the health and well-being of our employees and their families and have enacted measures to protect their health and safety.
- We are committed to combating COVID-19 by developing and manufacturing plasma-derived therapeutics on our proprietary hyperimmune platforms, as well as deploying our vaccine and contract development and manufacturing capabilities and expertise.
- We are committed to continuing critical ongoing clinical development programs and enterprise business operations.
- We are committed to the public health goal of “flattening the curve” and have mandated employees who can work from home to do so.
- We are committed to securing our supply chain and manufacturing infrastructure not only to deliver on our COVID-19 program goals, but also to ensure the continued availability of all our critical products and services to patients and customers.
- We are grateful for the committed support of all our employees and the trust our patients and customers have invested in us as we all navigate this evolving global emergency together.
Pharmaceutical and biotechnology companies play a critical role in protecting public health and we believe it is important that we continue to operate critical laboratory and manufacturing operations as part of this public health infrastructure. As it relates to COVID-19, Emergent may have an expanded role in the response to the pandemic. We are actively monitoring the situation and are working to ensure that our policies to prevent the spread of infection are balanced with our commitment to serve patients and customers during this evolving global emergency.